Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Breast cancer research : BCR. 2019 Mar 11. doi: 10.1186/s13058-019-1115-2. pii: 10.1186/s13058-019-1115-2
    PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL1,  Martin M2,  Holmes FA3,  Ejlertsen B4,  Delaloge S5,  Moy B6,  Iwata H7,  von Minckwitz G8,  Mansi J9,  Barrios CH10,  Gnant M11,  Tomašević Z12,  Denduluri N13,  Šeparović R14,  Kim SB15,  Jakobsen EH16,  Harvey V17,  Robert N18,  Smith J19,  Harker G20,  Zhang B21,  Eli LD22,  Ye Y23,  Lalani AS24,  Buyse M25,  Chan A26
    Author information
    1British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, V5Z4E6, Canada. schia@bccancer.bc.ca.
    2Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
    3Texas Oncology, P.A, Houston, TX, USA.
    4Rigshospitalet, Copenhagen, Denmark.
    5Institut Gustave Roussy, Villejuif, France.
    6Massachusetts General Hospital Cancer Center, Boston, MA, USA.
    7Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
    8Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-isenburg, Germany.
    9Biomedical Research Centre, Guy's Hospital, King's College London, London, UK.
    10Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil.
    11Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
    12Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
    13Virginia Cancer Specialists, Arlington, VA, USA.
    14University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.
    15Asan Medical Center, University of Ulsan, Seoul, Korea.
    16Lillebaelt Hospital, Vejle, Denmark.
    17Auckland City Hospital, Grafton, Auckland, New Zealand.
    18McKesson Specialty Health and The US Oncology Network, The Woodlands, TX, USA.
    19Compass Oncology, Portland, OR, USA.
    20Utah Cancer Specialists, Salt Lake City, UT, USA.
    21Puma Biotechnology, Inc., Los Angeles, CA, USA.
    22Puma Biotechnology, Inc., Los Angeles, CA, USA.
    23Puma Biotechnology, Inc., Los Angeles, CA, USA.
    24Puma Biotechnology, Inc., Los Angeles, CA, USA.
    25International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
    26Breast Cancer Research Centre-WA, Perth & Curtin University, Nedlands, Australia.
    Abstract

    BACKGROUND: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in women who completed trastuzumab-based adjuvant therapy for early breast cancer (EBC). We assessed the prognostic and predictive significance of PIK3CA alterations in patients in ExteNET.

    METHODS: Participants were women aged ≥ 18 years (≥ 20 years in Japan) with stage 1-3c (modified to stage 2-3c in February 2010) operable breast cancer, who had completed (neo)adjuvant chemotherapy plus trastuzumab ≤ 2 years before randomization, with no evidence of disease recurrence or metastatic disease at study entry. Patients were randomized to oral neratinib 240 mg/day or placebo for 1 year. Formalin-fixed, paraffin-embedded primary tumor specimens underwent polymerase chain reaction (PCR) PIK3CA testing for two hotspot mutations in exon 9, one hot-spot mutation in exon 20, and fluorescence in situ hybridization (FISH) analysis for PIK3CA amplification. The primary endpoint (iDFS) was tested with log-rank test and hazard ratios (HRs) estimated using Cox proportional-hazards models.

    RESULTS: Among the intent-to-treat population (n = 2840), tumor specimens were available for PCR testing (991 patients) and PIK3CA FISH (702 patients). Overall, 262 samples were PIK3CA altered: 201 were mutated (77%), 52 (20%) were amplified, and 9 (3%) were mutated and amplified. iDFS was non-significantly worse in placebo-treated patients with altered vs wild-type PIK3CA (HR 1.34; 95% CI 0.72-2.50; P = 0.357). Neratinib's effect over placebo was significant in patients with PIK3CA-altered tumors (HR 0.41; 95% CI 0.17-0.90, P = 0.028) but not PIK3CA wild-type tumors (HR 0.72; 95% CI 0.36-1.41; P = 0.34). The interaction test was non-significant (P = 0.309).

    CONCLUSIONS: Although there was a greater absolute risk reduction associated with neratinib treatment of patients with PIK3CA-altered tumors in ExteNET, current data do not support PIK3CA alteration as a predictive biomarker of response to neratinib in HER2-positive EBC.

    TRIAL REGISTRATION: ClinicalTrials.gov , NCT00878709 . Trial registered April 9, 2009.


    KEYWORDS: Breast cancer, Drug targets, Neratinib, PIK3CA, Predictive, Prognostic

    Publikations ID: 30867034
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt